US Food and Drug Administration commissioner nominee Robert Califf did his best to dodge tough questions and offer limited details on his plans for the agency if confirmed for a second stint as the agency’s leader at his 14 December Senate Health Committee hearing, but he did provide a few interesting hints at to how he would tackle some key drug regulatory issues.
Here’s a roundup of the insights gleaned from his mostly friendly interrogation from the US Senators with the most authority...